PYC Therapeutics (ASX:PYC) reported Thursday that its loss per diluted share in the fiscal first half widened to AU$0.0549, from a loss of AU$0.04 per diluted share a year earlier.
Analysts polled by Visible Alpha were expecting a diluted loss per share of AU$0.03.
Revenue for the six months ended Dec. 31, 2024, was AU$12.7 million, up 39% from AU$9.1 million in the same period last year. Analysts surveyed by Visible Alpha expected AU$11.4 million in total revenue.
Analysts polled by Visible Alpha expect earnings of AU$0.10 per diluted share on revenue of AU$18.7 for the full fiscal year.
The firm did not pay or declare any dividends during the period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.